Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-67.33k
- Incorporated2024
- Employees17.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
- Websitehttps://tevogen.com/
More ▼
Mergers & acquisitions
| Acquired company | TVGN:NMQ since announced | Transaction value |
|---|---|---|
| Tevogen Bio Inc | -92.18% | 1.41bn |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 588.00k | -53.93m | 126.29m | 56.00 | -- | 1.48 | -- | 214.78 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 127.60m | 28.00 | -- | 3.00 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 130.80m | 46.00 | -- | 1.11 | -- | 8.06 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 132.12m | 10.00 | -- | 0.6953 | -- | 66.06 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 132.89m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 133.21m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 137.38m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 137.40m | 37.00 | 20.20 | 4.68 | 18.54 | 2.35 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Mediwound Ltd | 19.85m | -12.75m | 139.07m | 100.00 | -- | 6.13 | -- | 7.01 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| ProQR Therapeutics NV | 14.43m | -28.72m | 142.72m | 157.00 | -- | 3.97 | -- | 9.89 | -0.3538 | -0.3538 | 0.1778 | 0.4423 | 0.0957 | -- | -- | 91,924.53 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 145.34m | 100.00 | -- | 5.23 | -- | 1.73 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Boundless Bio Inc | -100.00bn | -100.00bn | 145.99m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 147.00m | 5.00 | -- | 3.71 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 147.62m | 107.00 | -- | 0.6119 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Data as of Jun 14 2024. Currency figures normalised to Tevogen Bio Holdings Inc's reporting currency: US Dollar USD
4.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Portland Global Advisors LLCas of 31 Mar 2024 | 5.78m | 3.51% |
| Harraden Circle Investments LLCas of 10 Jan 2024 | 838.97k | 0.51% |
| Cantor Fitzgerald & Co.as of 31 Mar 2024 | 650.00k | 0.40% |
| Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 334.62k | 0.20% |
| HRT Financial LLCas of 31 Mar 2024 | 12.28k | 0.01% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 30.00 | 0.00% |
| Clear Street LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Jackson National Asset Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Centiva Capital LPas of 31 Mar 2024 | 0.00 | 0.00% |
| Koch Industries, Inc. (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 23 May 2024Source: FactSet Research Systems Inc.
